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Abstract 
 
The LTα1β2 and LIGHT TNF superfamily cytokines exert pleiotropic physiological functions 
through activation of their cognate lymphotoxin-β receptor (LTβR). Interestingly, since the 
discovery of these proteins accumulating evidence has pinpointed a role for LTβR signaling 
in carcinogenesis. Early studies have shown a potential anti-tumoral role in a subset of solid 
cancers either by triggering apoptosis in malignant cells or by eliciting an anti-tumor immune 
response. However, more recent studies provided robust evidence that LTβR signaling is 
also involved in diverse cell-intrinsic and microenvironment-dependent pro-oncogenic 
mechanisms, affecting several solid and hematological malignancies. Consequently, the 
usefulness of LTβR signaling axis blockade has been investigated as a potential therapeutic 
approach for cancer. Considering the seemingly opposite roles of LTβR signaling in diverse 
cancer types and their key implications for therapy, we here extensively review the different 
mechanisms by which LTβR activation affects carcinogenesis, focusing on the diverse 
contexts and different models assessed. 
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1. Introduction 
 
Lymphotoxin-β receptor (LTβR) is a member of the tumor necrosis factor receptor 
superfamily (TNFRSF) identified as a key mediator controlling the development, organization 
and homeostasis of lymphoid tissues and organs [1–3]. Moreover, it was reported to play a 
role in the adaptive immune response against pathogens [1], thymic medullary epithelial cell 
differentiation and central tolerance induction [4]. Currently it is known that LTβR is involved 
in many other biological processes such as liver regeneration [5], lipid homeostasis [6], high 
endothelial venule (HEV) differentiation and function [7], and protection against 
atherosclerosis [8]. Considering the immune system functions of LTβR signaling it is not 
unexpected that its deregulation leads to autoimmune and inflammatory diseases, including 
rheumatoid arthritis [9,10], Sjögren´s syndrome [11], autoimmune pancreatitis [12], hepatitis 
[13], and colitis [14]. Importantly, LTβR signaling has also been reported to be involved in 
cancer [15,16], albeit with contrasting, context-dependent effects. These effects and the 
current understanding of the LTβR signaling role in cancer development are the main focus 
of this review. 
 
2. LTβR and its ligands: lymphotoxin and LIGHT 
 
The human LTβR gene (LTBR or TNFRSF3) is located on chromosome (Chr) 12 (Figure 
1A), in proximity to genes encoding other TNFRSF members, namely TNFR1 (TNFRSF1A) 
and CD27 (TNFRSF7) [17,18]. The LTBR full-length transcript encodes a 435-amino acid 
type I glycosylated protein consisting of three main domains: extracellular (ECD), 
transmembrane (TMD), and intracellular domain (ICD), also known as cytoplasmic domain 
(CD) (Figure 1B). Like other TNFRSF receptors, LTβR displays four cysteine-rich domains 
(CRD) in the ECD, which confer receptor specificity and affinity for the cognate ligands [17], 
but it does not contain a death domain in the cytoplasmic tail. It rather harbors here a 
proline-rich membrane proximal region [17] and two binding sites for members of the TNF 
receptor-associated factor (TRAF) family of zinc RING finger proteins [19]. Indeed, TRAF2 
[20], TRAF3 [21], TRAF4 [22] and TRAF5 [23] have been reported to associate with LTβR. 
Moreover, within the TRAF-binding domain, distinct regions mediate self-interaction, 
receptor intracellular trafficking, and the activation of downstream signaling pathways like 
those activating NF-κB and those leading to cell death [24].  
LTβR has been shown to be constitutively expressed by a wide variety of cells in 
lymphoid and visceral tissues such as epithelial and endothelial cells, follicular dendritic cells 
(FDCs), fibroblasts, and myeloid lineage cells (e.g., monocytes, dendritic cells (DCs), and 
 3 
mast cells), but not on lymphocytes [14,18,25,26]. Since the only two known ligands for 
LTβR, lymphotoxin (LT) α1β2 heterotrimers and LIGHT/TNFSF14 homotrimers, are 
physiologically expressed in lymphocytes [27–29], this pattern of expression suggests that 
most if not all signals mediating LTβR activation are paracrine or juxtacrine in nature.  
 The genes encoding LTα, the TNF superfamily (TNFSF) member 1 (TNFSF1 or LTA) 
and LTβ, the TNFSF member 3 (TNFSF3 or LTB), reside in a tightly linked locus within the 
MHC class III region in human Chr 6, flanking the gene encoding TNFα (TNFSF2 or TNFA) 
(Figure 1A) [30–33]. The human full-length LTα mRNA encodes a 205-amino acid type II 
glycosylated protein, also known as TNFβ [33], while the full-length LTβ mRNA encodes a 
244-amino acid type II glycosylated protein [30]. In contrast to the LTβ protein, which 
comprises a short N-terminal CD, a TMD and a C-terminal ECD [30], LTα lacks a TMD 
(Figure 1B). Therefore, when expressed in the absence of LTβ, LTα forms soluble LTα3 
homotrimers stabilized primarily by interactions between hydrophobic and aromatic side 
chains [18,34,35]. When LTα is expressed together with LTβ, these proteins oligomerize 
generating cell-surface LTα1β2 heterotrimers [18,36,37]. LTα2β1 heterotrimers can also form, 
but these are a minor form detectable only in vitro and representing less than 10% of total 
LTαβ heterotrimers [37]. The LTα subunit contributes primarily to the conformation of the 
heterotrimer [35], while the LTβ subunit provides the membrane anchor for LTα1β2 and 
confers specificity for LTβR binding [17]. LTB but not LTA expression in lymphocytes is 
constitutive but both are induced by cell stimulation [30]. The reported basal levels of LTB 
mRNA in lymphoid cells may be important to interact with and transport LTα to the cell 
surface as an LTα1β2 heterotrimer (instead of LTα2β1 or even soluble LTα3). Being inducible, 
LTα production is probably the rate-limiting step in this process [30,38,39].  
The LTα- and LTβ-encoding genes display a restricted and similar pattern of 
expression, being mainly expressed in hematopoietic cells including activated T and B cells, 
natural killer (NK) cells [27,29], DCs [40] and lymphoid-tissue inducer (LTi) cells [41]. Cell-
surface LTα1β2 heterotrimers are upregulated through lymphocyte activation, but also by 
cytokine and chemokine induction. For example, LTα1β2 is induced by IL-2 on human 
peripheral blood T cells [29], and IL-4, IL-7, CCL19 and CCL21 in murine splenic T cells [42]. 
Induction of LTα1β2 expression by viral proteins in infected hepatocytes [13,43] and cervical 
epithelium [44] was also reported.  
 The other known LTβR ligand is encoded by the human TNFSF member 14 
(TNFSF14) or LIGHT gene and is located within an MHC paralog region on Chr 19, in close 
proximity to other TNFSF genes such as those encoding CD27L/CD70 (TNFSF7) and 
CD137L/4-1BB (TNFSF9) (Figure 1A) [45,46]. The LIGHT full-length transcript is translated 
into a 240-amino acid glycosylated type II transmembrane protein (Figure 1B) [45]. LIGHT 
monomers form homotrimers at the cell surface of activated lymphocytes [28], which can be 
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shed upon proteolytic cleavage [45]. Similarly to lymphotoxin genes, the LIGHT-encoding 
gene displays a restricted expression pattern being mainly expressed on activated 
peripheral blood T lymphocytes [28], monocytes, granulocytes and immature DCs 
[40,47,48], and also on mucosal tissue-derived CD4+ T and NK cells [49]. LIGHT was shown 
to be expressed also in thymic stromal cells such as DCs, fibroblasts, and endothelial and 
epithelial cells [26].  
 Some TNFSF members can bind the same receptor, as is the case for LTα/LTβ-
containing ligands and LIGHT. LTα3 binds TNFR1, TNFR2 [50,51], and herpes virus entry 
mediator (HVEM) [28,50], a receptor expressed by T and B cells, NK cells, DCs and 
monocytes [52]. Since the LTβR discovery, no other receptor for LTα1β2 has been found [37]. 
In contrast, LTα2β1 heterotrimers may bind not only LTβR, albeit with low affinity [17,35,37], 
but also TNFR1 and TNFR2 [17,37]. LIGHT forms only homotrimers, which can bind and 
activate LTβR and HVEM [28], and the soluble decoy receptor 3 (DcR3), which acts as a 
negative regulator [53]. Although several of these interactions were reported in vitro (e.g. 
LTα2β1 binding to TNFR1/2), their physiological relevance in vivo remains questionable.  
Even though both LTα1β2 heterotrimers and LIGHT homotrimers are often found at 
the cell membrane, in certain contexts they can be shed from the cell surface. For instance, 
LTα1β2 can be shed from human activated T cells, upon proteolysis mediated by matrix 
metalloproteinase (MMP)-8 and ADAM17/TNFα converting enzyme (TACE), to induce the 
expression of pro-inflammatory genes on synovial fibroblasts from rheumatoid arthritis 
patients [10]. LIGHT can also be actively shed from the cell surface of CD4+ T lymphocytes 
by MMPs in rheumatoid arthritis [54] but also in the context of immune cell regulation [55]. 
Although the soluble form of LIGHT binds and activates HVEM, the membrane-bound 
homotrimer shows enhanced activation of this receptor [45,56,57]. Interestingly, the 
membrane-bound form of LIGHT expressed in T lymphocytes has been shown to act as a T-
cell receptor (TCR) costimulatory signal when bound either to an agonistic antibody or to its 
receptor DcR3, a phenomenon denominated reverse signaling [58,59]. Nevertheless, the 
biological significance of these different LIGHT forms is still not fully understood especially 
regarding LTβR activation. In certain contexts LIGHT shedding may induce distal functional 
effects on LTβR activation or may serve as a mechanism of self-inactivation [45].  
 
3. LTβR activation, NF-κB signal transduction and target gene regulation 
 
The TNFRSF members are typically activated by ligand-induced trimerization or even higher 
order oligomerization through the interaction of receptor CRD domains with each monomer-
monomer interface groove [60]. As no exception to this notion, the central initiating event for 
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LTβR signaling is receptor aggregation. However, unlike other TNF receptors, each LTβR 
subunit can bind only two sites in the LTα1β2 heterotrimer, the LTα-LTβ (higher affinity) and 
LTβ-LTβ’ (lower affinity) interfaces for productive receptor activation [61]. Similarly, LIGHT 
has been shown to present only two high-affinity binding sites for LTβR [62]. Thus, the 
binding of LTα1β2 or LIGHT to LTβR brings two receptor molecules in close proximity (Figure 
1C) [61,62] and the LTβR self-interaction region in the cytoplasmic domain promotes 
receptor aggregation and consequent conformational changes [24]. These events lead to the 
sequential recruitment of cytosolic adaptor proteins to the cytoplasmic region of LTβR, 
mainly TRAF proteins. These proteins may activate or repress signaling initiation leading to 
gene transcription through different signaling pathways such as the classical and the 
alternative NF-κB pathways, the c-Jun N-terminal kinase (JNK) MAP kinase pathway, and 
other signaling pathways leading to cell death [63] (Figure 2). LTβR-dependent downstream 
signaling can also be initiated independently of ligand binding either artificially by anti-LTβR 
agonistic antibodies that induce receptor aggregation [21,64], or pathologically by receptor 
overexpression leading to self-association [19,65,66].  
Although LTβR activation has been reported to induce gene expression through 
ASK-MKK-JNK-dependent AP-1 activation [67,68] and LTβR interacts with the AP2 
adaptor/clathrin complex to mediate unknown NF-κB-independent functions [19], cell death 
induction and NF-κB activation are the most studied events downstream LTβR. Despite 
lacking a cell death domain in its cytosolic domain, LTβR has been shown to induce death of 
cancer cell lines (e.g., HT-29, WiDr, Hep3BT2, and MCF-7) and to arrest tumor growth in 
cell line-derived xenograft models [69,70]. LTβR activation was shown to lead to cell death in 
the presence of IFN-γ [69] by either caspase-dependent (apoptosis) and/or caspase-
independent (necroptosis/necrosis) mechanisms [20,71–74]. In addition, LTβR activation in 
combination with TNFR1 was proven essential to sensitize cortical thymic epithelial cells 
(cTECs) to TNFR1-mediated cell death [75,76]. The mechanism was shown to rely on NIK 
activation and on assembly of the RIP1/FADD/caspase8 death complex (Figure 2), but not 
on processing of p100 to p52, an essential step in the NF-κB alternative pathway [77]. 
Despite these findings, further research is warranted to fully understand the mechanisms of 
cell death induced by LTβR, which may depend on cell type, nature of the LTβR-activating 
stimulus and co-activation of other receptors.  
Unlike the prototypical TNF receptors, which activate the classical but not the 
alternative NF-κB pathway (i.e., TNFR1), but like other TNFRSF members (e.g., BAFFR, 
CD40, CD27, Tweak, and CD30), LTβR binding by its ligands leads to both classical and 
alternative NF-κB pathway activation [19,78]. The activation of one or the other NF-κB 
signaling pathway is spatially and temporally regulated by LTβR trafficking [19] and varying 
levels of receptor cross-linking may be required for distinct conformational changes and 
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activation of different signal transduction pathways. Furthermore, the classical and the 
alternative NF-κB signaling pathways control distinct patterns of gene expression [78] and 
are therefore differentially involved in various functions attributed to LTβR signaling (Figure 
2).  
To activate the classical NF-κB signaling pathway, LTβR engagement leads to 
TRAF2 recruitment to its CD and subsequent IKK-mediated IκBα phosphorylation and 
degradation by the proteasome [79]. These events lead to p50-RelA heterodimer activation 
[78,80]. When upregulated, TRAF3 was shown to inhibit TRAF2 recruitment to LTβR, thus 
negatively regulating NF-κB activation [79]. When LIGHT or LTα1β2 accumulates at the 
surface of LTβR-inducing cells, higher-order clusters of LTβR may form on the target cell 
that seemingly trigger dynamin-2-dependent endocytosis of the receptor [19]. During this 
process, the LTβR CD was shown to remain exposed towards the cytosol and to compete 
with NIK for the binding of its inhibitory complex composed by TRAF3/TRAF2/cIAP1/cIAP2 
[81,82]. As a consequence, the constitutive proteasomal degradation of NIK is alleviated, 
leading to NIK accumulation and activation of IKKα. These events lead to p100 processing 
to p52 and the translocation of p52/RelB dimers to the nucleus (Figure 2) [19,83]. LTβR-
mediated activation of alternative NF-κB signaling is terminated by a mechanism of negative 
feedback control relying on IKKα-dependent destabilization of NIK [84]. Thus, TRAF3 inhibits 
NF-κB signaling by being part of a complex that mediates NIK targeting to proteasome 
degradation and, thus inhibits the processing of p100 to p52 [79,85]. Regarding kinetics, 
ligand binding to LTβR can induce a rapid and transient activation of the classical NF-κB 
pathway, followed by a delayed but sustained activation of the alternative pathway [78,80]. 
The delayed activation of the alternative pathway may be at least partially due to the 
requirement for increased Nfkb2 gene transcription (encoding p100), which is mediated by 
the IKKβ-dependent classical pathway [78,80]. Alternatively, it was proposed that LTβR 
activation induces the IKKα-dependent alternative pathway alone, resulting in p100 
degradation and eventually activating RelA-containing and RelB-containing dimers [86]. 
Through the activation of p50/RelA heterodimers, LTβR signaling promotes for instance the 
upregulation of proinflammatory molecules including the CCL4/macrophage inflammatory 
protein (MIP)-1β, CXCL2/MIP-2 and vascular-cell adhesion molecule 1 (VCAM-1) in mouse 
embryonic fibroblasts (MEFs) [78], and CXCL1, CXCL2, intercellular adhesion molecule 1 
(ICAM-1), VCAM-1, and E-selectin in endothelial cells [87]. Conversely, LTβR-mediated 
activation of p52/RelB heterodimers results in the production of lymphoid chemokines such 
as the CCL19/EBl1-ligand chemokine (ELC), CCL21/secondary lymphoid tissue chemokine 
(SLC), CXCL12/stromal cell-derived factor-1α (SDF-1α), CXCL13/B lymphocyte 
chemoattractant (BLC) and the cytokine B cell activation factor (BAFF), being all involved in 
lymphoid organogenesis and homeostasis [26,78].  
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4. Physiological roles of lymphotoxin signaling 
 
LTα1β2/LIGHT-induced LTβR signaling is critically involved in lymphoid organogenesis and 
maintenance of secondary lymphoid structures, in addition to its roles in regulation of innate 
and adaptive immune response, inflammation, and tissue homeostasis.  
Lymphoid organogenesis is largely associated with LTβR signaling induced by the 
LTα1β2 heterotrimer, as shown by studies blocking ligand-receptor interaction [88,89] or 
using LTβR, LTα, LTβ or LIGHT knockout mice [1–3,90]. LTβR knockout mice lack several 
secondary lymphoid organs, including peripheral and mesenteric lymph nodes (LNs), 
Peyer´s patches and gut-associated lymphoid tissues (GALT) [1]. LTα knockout mice 
generally lack peripheral and mesenteric LNs and Peyer´s patches, although mesenteric 
lymphoid aggregates were observed in a few mice [3,91]. LTβ knockout mice lack most LNs, 
but in contrast to LTα and LTβR-deficient mice conserved fully organized mesenteric LNs 
and cervical lymph node-like structures [2,92]. Mesenteric LN development was impaired by 
simultaneous LTβ and LIGHT inactivation, meaning that LIGHT can compensate for LTβ 
absence in mesenteric LN development [90]. In addition, LTα-, LTβ- and LTβR-deficient 
mice, but not LIGHT-deficient mice presented splenic structural defects. Discrepancies in the 
effects of ligand-receptor gene inactivation led to the supposition, yet to be confirmed, that 
either an alternative unknown ligand for LTβR or other nonspecific interactions could 
account for such phenotypic differences [1–3].  
In the adult, LTβR signaling was reported to be critically involved in the adaptive 
immune response against pathogens due to its intervention in processes such as DC 
homeostasis and expansion [93,94], and lymphocyte maturation and survival [95–98]. 
Furthermore, its activation is continuously required for the maintenance of the integrity and 
organization of microenvironments from secondary lymphoid organs [1,88,89]. For example, 
LTβR is important for the development and structural maintenance of fibroblastic reticular 
cells (FRCs) in LNs and spleen [99,100]. In the spleen, LTβR activation was also shown to 
be essential for FDC differentiation [101]. Accordingly, LTβR-deficient mice present 
disrupted FDC and germinal center formation and, consequently deficient B cell affinity 
maturation [1]. LTβR signaling is also important for the trafficking of lymphoid and other 
hematopoietic cells, namely the recruitment, migration and organization inside organs, and 
the migration to other tissues [4,26,42,102]. Moreover, it is involved in the regulation of acute 
inflammatory reactions and in the development of inflammation-associated ectopic lymphoid 
structures [41,103]. In the latter process, LTβR-dependent stromal cell differentiation into 
reticular networks and induction of chemokines, cytokines and adhesion molecules play a 
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critical role. Finally, LTβR activation favors the recruitment of hematopoietic cells to lymphoid 
compartments by instructing the development and function of high endothelial venules 
(HEVs) [7,104]. 
Importantly, LTβR signaling leading to NIK/IKKα-dependent alternative NF-κB 
activation has been shown to be a key player for thymic medullary epithelial cell 
differentiation [105] and the maintenance of the thymic structure [4], considered essential for 
central tolerance induction. In this context, T cell development and selection, and the 
maintenance of the thymic microenvironments require reciprocal interactions between 
thymocytes and stromal cells where LTβR signaling is a critical mediator of this thymic 
crosstalk [4]. In addition, cTEC cell death mediated by LTβR and TNFR1 combined and NIK 
activation was proven essential for thymic involution in pathological conditions [75–77]. 
Although LTβR and its ligands are widely recognized as key players in immunity, 
they are also involved in many other biological processes such as liver regeneration [5,106], 
hepatic lipid metabolism [6], and adipocyte differentiation [107]. Importantly, LTβR signaling 
has also been reported to be involved not only in cell death and tumor growth inhibition, but 
also in cancer development and progression [15,16]. 
 
5. LTβR suppressor functions in solid tumors 
 
5.1. LTβR activation leading to cancer cell death 
The lymphotoxin designation was first attributed upon LTα identification as a cytokine similar 
to TNFα that presented cytolytic/cytostatic effects on target cells [108]. Indeed, LTβR 
activation was first shown to mediate cytotoxic effects in tumors, thus pointing to a potential 
anti-cancer therapy, especially because this receptor was found to be expressed in a wide 
range of tumor types [65,70,73].  
The direct anti-cell growth role of LTβR has been demonstrated in a subset of human 
epithelial cancer cell lines (e.g., HT-29, WiDr, Hep3BT2, MCF-7, and HeLa), where LTβR 
activation was shown to induce death with slow kinetics (36-72 h) either in the presence of 
IFN-γ [69,71] or through LTβR ligand-independent self-association caused by 
overexpression [66]. Furthermore, LTβR activation was reported to arrest tumor growth in 
mice xenografted with colorectal cancer cell lines and patient samples [69,70]. The 
molecular mechanism by which LTβR contributes to cancer cell line death has however 
remained elusive. 
To study LTβR-induced anti-growth effects in cancer, Hu and coworkers used a lung 
experimental metastasis model in which mouse colon carcinoma cells were injected i.v. into 
BALB/c mice and found that CD11b+ myeloid cells, NK cells, and CD8+ and CD4+ T cells 
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collected from lung metastases expressed LTα1β2 and LIGHT [73]. This observation 
supported a previous report indicating that monoclonal antibody (mAb)-mediated LTβR 
activation in established CT26 cell line-derived subcutaneous tumors led to both T cell 
infiltration, probably mediated by pro-inflammatory chemokines, and tumor necrosis [70]. 
Supporting the notion that immune cells interact with tumor cells through LTβR to suppress 
spontaneous tumor development, recombinant LTα1β2 and LIGHT proteins or an agonist 
LTβR mAb could inhibit in vitro growth of human colon carcinoma and soft tissue sarcoma 
cell lines [73]. Likewise, using a syngeneic mouse model of sarcoma metastasis to the lung 
together with adoptive transfer of tumor-specific cytotoxic T lymphocytes (CTL), Yang and 
co-workers previously showed that LTβR was a direct effector of CTL-mediated tumor 
rejection in vivo [109]. Regarding the mechanism, LTβR stimulation by an agonistic mAb 
induced caspase- and mitochondrial-dependent apoptosis and activated classical and 
alternative NF-κB pathways in human cancer cell lines [73]. Furthermore, NF-κB inhibition 
promoted CT26 colon cancer cell metastatic potential in vivo, suggesting that in this context 
LTβR-mediated apoptosis and activation of the NF-κB signaling pathway might act in concert 
to suppress tumor development [73].  
It has been suggested that LTα1β2 and LIGHT ligand expression by immune cells 
such as T cells [109], NK cells [110] or DCs [111] may engage LTβR on tumor cells and thus 
trigger antitumor cytotoxicity. Yet, tumor cell death in these studies was induced by 
recombinant ligands and/or LTβR agonistic antibodies, which may not reflect the 
physiological levels and activity of ligands expressed at the surface of immune cells. This 
caveat is underscored by results showing that LTβR activation and downstream signaling 
pathways induced in vitro by recombinant ligands or agonistic antibodies may depend on the 
duration and degree of receptor oligomerization [64]. Nevertheless, LTβR-mediated tumor 
suppression by either agonistic mAbs [69,70] or adoptively transferred tumor-specific CTLs 
[109] was put forward as a therapeutic approach to halt tumor growth and to override colon 
carcinoma and soft tissue sarcoma chemo- and radiotherapy resistance [70,73]. 
 
5.2. LTβR or HVEM activation leading to immune-mediated tumor rejection 
5.2.1. LIGHT-induced recruitment and activation of anti-tumoral lymphocytes 
Rather than identifying a direct effect of LTβR signaling in tumor regression, Winter and 
coworkers found that LTβR-mediated tumor regression could occur through an indirect 
pathway [112]. These authors used an experimental pulmonary metastasis model generated 
by intravenous injection of the D5 melanoma cell line (a B16 cell line subclone) in syngeneic 
mice, and found that infiltrating effector T cells, which expressed LTβR ligands, activated 
LTβR but did not induce apoptosis of D5 tumor cells in vitro. Instead, LTβR activation in D5 
melanoma cells induced the secretion of chemokines that mediate macrophage migration 
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[112]. Although, direct anti-tumor effects could not be excluded, this report indicates that 
LTβR activation by LTα1β2 and/or LIGHT is involved in the induction of chemotactic 
molecules that create a tumor microenvironment favorable for lymphocyte homing, which in 
turn may boost anti-tumor immunity and contribute to tumor suppression. Also in this 
context, Yu and colleagues disclosed a role for LTβR signaling in tumor immune rejection 
[113]. LIGHT overexpression in a fibrosarcoma cell line that was then subcutaneously 
inoculated in C3B6F1 mice induced LTβR-mediated CCL21 and MAdCAM-1 expression in 
tumor microenvironmental cells. This in turn led to CD8 naïve T cell infiltration and 
activation, leading to the rejection of the established tumor. Furthermore, direct inoculation 
of LIGHT-expressing tumor cells in established non-LIGHT-expressing primary tumors led to 
their regression. Primary tumor rejection was also achieved when LIGHT-expressing tumor 
cells were inoculated in another subcutaneous site, indicating that LIGHT can generate a 
systemic immune response against distal tumors. These data support the rationale of using 
LIGHT-expressing tumor vaccines as a therapeutic tool [113]. In this line, other researchers 
genetically engineered attenuated Salmonella to express LIGHT and used it as a targeting 
vehicle for local expression of LIGHT in tumors. This approach led to LTβR and HVEM-
dependent inhibition of both primary and metastatic tumor growth in subcutaneously injected 
syngeneic immunocompetent mice [114]. LIGHT expression induced both T and B 
lymphocyte infiltration and production of the CXCL9 chemoattractant in subcutaneous 
tumors, but it remained to be established whether these two effects were causatively linked 
[114]. LIGHT expression was also found to be frequent in patient-derived metastatic 
melanoma cells and in melanoma cell line-derived microvesicles, and to be correlated with 
T-cell infiltration [115]. In addition, another approach based on LIGHT-expressing 
adenovirus was tested for local tumor treatment. These viruses initiated priming of tumor-
specific CD8+ T cells directly in the primary tumor, followed by the exit of CTLs, which 
homed to distal tumors to elicit immune-mediated eradication of spontaneous metastases 
[116]. Several studies therefore indicate that LIGHT is a potent primer of T-cell responses 
that can counter tumor growth and that it can be used as a therapeutic tool.  
 
5.2.2. LTβR-mediated HEV differentiation and recruitment of anti-tumoral lymphocytes 
In addition to its role in chemokine production and chemoattraction, LTβR activation was 
shown to correlate with lymphocyte extravasation through HEVs and tumor infiltration, thus 
leading to tumor regression [117,118]. HEVs are specialized postcapillary vessels of 
secondary lymphoid organs, also found in chronically inflamed non-lymphoid tissues [119] 
and tumors [120]. These vessels mediate the extravasation of naïve and central memory 
lymphocytes from the peripheral blood to lymphoid tissues to initiate immune responses 
[121], and express LTβR, which is required for HEV differentiation and function [7]. In this 
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context, Martinet and coworkers have recently found that in human breast cancer, higher 
numbers of LTα1β2-expressing DCs were correlated with increased HEV density and T and 
B lymphocyte infiltration. Moreover, LTβ expression correlated with expression of 
chemokines associated with HEV-mediated lymphocyte extravasation (CCL19, CCL21 and 
CXCL13) [118]. Interestingly, these authors showed that the tumor HEV density was 
inversely correlated with breast cancer progression, from in situ ductal carcinoma to invasive 
ductal carcinoma, and found that high density of HEVs in breast tumors was correlated with 
a favorable prognosis [118]. These findings contradict the generally accepted assumption 
that tumor angiogenesis correlates with tumor progression and worse prognosis, and 
highlight the notion that different types of tumor blood vessels play distinct roles. A similar 
mechanism was also found in a mouse model of methylcholanthrene-induced fibrosarcoma, 
in which depletion of T regulatory cells (Tregs) led to HEV development, T-cell infiltration, 
LTα and LTβ upregulation and decreased tumor growth [117]. 
 In summary, LTβR can mediate anti-tumor effects by direct cytotoxicity (Figure 3A) 
but also by other indirect mechanisms, like tumor cell sensitization to chemotherapeutic 
agents and radiation [70]. Furthermore, LTβR can stimulate host-mediated anti-tumor 
immune responses either by inducing the expression of pro-inflammatory cytokines and 
chemokines that chemoattract and activate lymphocytes [70,112] (Figure 3B), or by inducing 
the differentiation of HEVs that mediate lymphocyte trafficking to both normal organs and 
tumors [7,118] (Figure 3C) .  
 
6. LTβR-mediated promotion of solid tumors 
 
In contrast to the previously discussed anti-cancer roles of LTβR, a tumor-promoting role for 
this receptor has been disclosed in a wide variety of contexts. Cancer cells from different 
origins express LTβR [65,70,73], being often this expression increasingly more prevalent 
with cancer progression and metastasis [65,73,122]. Furthermore, LTBR gene upregulation 
or structural alterations leading to LTβR constitutive activation were reported to correlate 
with carcinogenesis [65,122–124] (Figure 4A). As shown below, LTβR is thought to promote 
oncogenesis either by directly fostering survival and/or proliferation of malignant cells or by 
generating a pro-tumorigenic inflammatory microenvironment. 
 
6.1. LTBR genetic alterations leading to LTβR constitutive activation 
An early study reporting an LTβR pro-tumorigenic role identified an NH2-terminally truncated 
form of LTβR in a pancreatic ductal carcinoma cell line. This truncated receptor as well as 
the full-length LTβR protein were shown to have fibroblast transforming activity in vitro and in 
vivo, even in the absence of their cognate ligands [123]. In another study, the 12p13.3 
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region, including the LTBR locus, was found to be in higher copy number in 51% and 
amplified in 7% of nasopharyngeal carcinoma (NPC) cases [122]. Additionally, LTβR protein 
was found to be frequently overexpressed in NPC tumors. Subsequently, LTβR 
overexpression in an immortalized nasopharyngeal epithelial cell line was shown to 
contribute to ligand-independent cell proliferation. Importantly, LTβR knockdown inhibited in 
vivo tumor growth in an NPC xenograft mouse model [122]. Since LTβR stimulation 
activated NF-κB in nasopharyngeal cells [122], the same authors showed that in cases 
without evident LTBR amplification genetic alterations affecting other NF-κB signaling 
regulators (TRAF3, TRAF2, NFKBIA, and A20/TNFAIP3) were present [125]. These results 
therefore support a role for LTβR-mediated NF-κB activation in NPC development. 
The oncogenic potential of LTβR has also been reported in melanoma. Dhawan and 
co-workers have shown that LTβR expression is upregulated in human metastatic 
melanoma samples when compared to normal melanocytes and other melanoma lesions. In 
melanoma cell lines, LTβR activates the NF-κB pathway and induces cell proliferation and 
invasiveness, all in a ligand-independent manner [65]. These findings suggest that, like in 
pancreatic cancer, the elevated expression of LTβR in melanoma is by itself sufficient to 
drive cancer progression.   
 
6.2. Ligand-dependent activation of LTβR in cancer development 
Despite reports indicating that LTβR signaling can be activated in the absence of ligands, 
other studies have shown that these may play important roles in promoting cancer. Genetic 
studies in humans identified single nucleotide polymorphisms (SNPs) in the LTα gene that 
may be either cancer-protective or lead to an increased cancer risk. For example, one 
common SNP, LTA +252A>G or rs909253, was described in meta-analysis studies to be 
positively associated with cancer susceptibility to different types of cancer [126,127]. Such 
susceptibility was also found for specific cancer types, such as non-Hodgkin lymphoma 
[128,129], breast cancer [130,131] and gastric cancer [132,133]. Despite conflicting data on 
the association between LTA gene polymorphisms and risk for different types of cancer in 
different ethnic populations, and on whether the polymorphic allele is present in 
homozygosity or heterozygosity, it was reported that different LTA alleles may result in 
differential gene transcription and protein expression [134,135]. Since LTα plays a key role 
in immunity and inflammation [136], alterations in its production may affect anti-cancer 
immunity and inflammation-induced cancer. Yet, the exact mechanism by which it affects 
cancer risk in each context remains to be defined. Furthermore, the involved LTα-containing 
ligand, either LTα3 homotrimer or LTα1β2 heterotrimer, was not determined by these studies. 
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6.3. LTβR pro-oncogenic roles mediated by interactions with the tumor microenvironment 
Immune cells are the main source of LTβR ligands and the interaction of these cells with 
tumor cells can either restrain, as discussed above, or promote tumor progression. Tumor 
and/or stromal cells respond to injury, infection and tissue stress by producing cytokines and 
chemokines that attract immune cells [137]. As a result, these cells migrate to the tumor 
microenvironment where they secrete inflammatory, pro-angiogenic and pro-tumorigenic 
factors that may affect tumor progression and metastasis. Thus, depending on the tumor 
microenvironment chemokine milieu, tumor-infiltrating immune cells can stimulate the 
immune response against tumor cells or rather help these to subvert the immune response 
and promote oncogenesis. As a signaling axis involved in immune cell communication, in 
addition to its involvement in the induction of tumor-suppressive microenvironments, as 
discussed above, LTβR signaling can also contribute for the induction of pro-oncogenic, 
inflammatory microenvironments. A wide range of studies have shown that inflammation can 
promote tumorigenesis by promoting angiogenesis, release of growth and survival factors, 
invasiveness, metastasis and evasion of host defense mechanisms [138].  
 
6.3.1. LTβR-induced angiogenesis 
The importance of angiogenesis for the growth of solid tumors has since long been 
recognized. As tumor growth and metastasis require persistent new blood vessel formation, 
a developing tumor shifts from the avascular phase to the angiogenic phase, the so-called 
angiogenic switch [139]. This switch is controlled by a balance between pro- and anti-
angiogenic factors, which are secreted by the tumor cells themselves or by cells in the tumor 
microenvironment, in particular resident stromal cells and immune cells. It is known that the 
expression of pro- and anti-angiogenic factors by cancer cells can be controlled either 
directly by oncogenes, tumor suppressor genes and transcription factors or indirectly by 
extrinsic factors. Yet, the roles and the interplay among the various inflammatory cytokines 
and chemokines in the angiogenic switch are still poorly understood. 
In this context, Hehlgans and co-workers have shown that inhibition of LTβR 
signaling can block angiogenesis and tumor growth [140,141]. Using methylcholanthrene-
induced murine fibrosarcoma BFS-1 cells, these authors have shown that LTβR activation 
by LTα1β2- or LIGHT-expressing T and B lymphocytes induced the expression of the 
angiogenic mediator CXCL2 [140]. CXCL2 induction in BFS-1 cells depended on NF-κB 
activation and contributed for solid tumor growth in vivo. The described pro-tumorigenic 
effect was assumed to be due to the modulation of the tumor microenvironment through 
LTβR-mediated angiogenesis induction (Figure 4B) because LTβR inhibition blocked BFS-1 
tumor angiogenesis while direct LTβR stimulation (with an agonistic anti-LTβR monoclonal 
antibody) did not increase proliferation or survival of fibrosarcoma cells [141].  
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6.3.2. LTβR-induced chronic inflammation 
Tumors often arise in sites of chronic inflammation [142], which provide a microenvironment 
containing various mediators (e.g., cytokines, chemokines, and prostaglandins) with tumor-
promoting properties, including enhanced cell proliferation, survival, angiogenesis and 
migration. In this context, Haybaeck and co-workers have found the involvement of LTβR 
signaling in the development of virus-induced chronic hepatitis and hepatocellular carcinoma 
(HCC) [13]. In hepatic primary tissue from hepatitis B or C (HBV- or HCV)-induced chronic 
hepatitis and HCC patients, these authors found upregulation of not only LTβR and its 
ligands (LTα, LTβ and LIGHT) but also pro-inflammatory chemokines (CCL2, CCL3 and 
CXCL10). LTBR was highly expressed in liver cell populations depleted of hematopoietic 
(CD45-positive) cells, while LTA, LTB and LIGHT were expressed both in hematopoietic and 
non-hematopoietic HCV-induced hepatitis and HCC liver cell fractions. Furthermore, 
expression of LTBR, LTA, LTB, LIGHT and inflammatory chemokines in a human 
hepatocyte cell line Huh-7.5 was shown to be directly linked to the presence of HCV 
infection. In transgenic mice expressing high levels of LTα and LTβ in a liver-specific 
manner, LTβR signaling induced chronic hepatitis characterized by inflammation, T and B 
lymphocytic infiltrates and hepatocyte apoptosis. Further experiments demonstrated that T 
and B cells, which express LTβR ligands, and LTβR-mediated canonical NF-κB signaling 
activation in hepatocytes were both required for LTβR-induced chronic hepatitis and HCC 
development [13]. These findings indicate that persistent lymphocyte-derived LTα1β2 and 
LTβR-induced NF-κB activation are tumor-promoting, and that rather than having direct 
oncogenic properties, LTβR signaling reshapes and generates an inflammatory, oncogenic 
hepatic microenvironment (Figure 4C). Interestingly, it was recently reported that short-term 
LTβR stimulation led to degradation of HBV-derived covalently closed circular DNA 
(cccDNA) in infected hepatocytes [143]. This anti-HBV effect was shown to be mediated by 
LTβR-induced APOBEC3B deaminase expression and indicates that LTβR agonists could 
be incorporated in anti-HBV combined therapeutic regimens [143]. Importantly, these data 
suggest that in contrast to the HCC-causing inflammation-related persistent LTβR 
stimulation, transient stimulation may actually prevent HBV-induced HCC. 
 Supporting the aforementioned studies on hepatitis and HCC [13], Simonin et al. 
(2013) have shown in a recent report that LTβ expression can be induced by the HCV NS5B 
polymerase in a human hepatoma cell line. Using transgenic mice with hepatocyte-targeted 
expression of the entire ORF of the genotype 1b HCV, Simonin and co-workers have also 
shown that LTβ hepatocyte expression in HCV transgenic liver tumors was associated with 
NF-κB activation, chemokine synthesis and intra-tumoral recruitment of macrophages and T 
and B lymphocytes [43]. In addition to these studies on viral-induced HCC, LTβR was shown 
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to be also involved in the pathogenesis of non-viral HCC. Using a mouse model of long-term 
choline-deficient high-fat diet, Wolf et al. (2014) identified CD8+ T cells and NKT cells 
recruited to the liver as key players in the development of steatosis and HCC. These cells 
were shown to interact with hepatocytes leading to their activation and to the release of 
soluble factors such as LIGHT and lymphotoxin. In addition, LTβR and classical NF-κB 
signaling were shown to be activated in hepatocytes, thus facilitating liver tumorigenesis 
[144]. More recently, LTβR signaling was found to participate in oncogene-driven HCC 
progression [145]. In an HCC mouse model initiated by constitutively active Akt (in 
combination with mutated β-catenin or Notch1), LTβ and LTβR expression were found to be 
upregulated in liver tumors. More importantly, blockade of LTβR signaling reduced tumor 
progression and prolonged mouse survival [145]. Together, these reports demonstrate that 
independently of the causing agent, LTβR persistent signaling in the context of chronic 
inflammation promotes HCC progression, and may be a potential therapeutic target. 
Cancer therapy-induced cell death can also elicit an inflammatory response that may 
contribute to therapeutic resistance. This is the case of castration-resistant metastatic 
prostate carcinoma, the emergence of which constitutes a major complication limiting the 
success of androgen ablation therapy and underlying most prostate cancer-associated 
mortality. Using two animal models, the SV40 large T antigen-driven transgenic 
adenocarcinoma mouse prostate (TRAMP) cancer model and the mouse androgen-
dependent CaP prostate cancer cell line subcutaneously allografted in castrated FVB mice, 
Ammirante et al. (2010) unveiled a mechanism underlying the emergence of castration-
resistant prostate cancer. These researchers found that following androgen ablation 
therapies, the death of androgen-deprived primary cancer cells induced an inflammatory 
response with concomitant production of CXCL13 and other inflammatory chemokines, and 
recruitment of leukocytes, mostly B cells, into the regressing tumor. IKKβ activation in B 
cells, presumably by inflammatory cytokines, induced the expression of surface LTα1β2 in 
these cells. These LTα1β2-expressing B cells led to LTβR activation and IKKα nuclear 
translocation in prostate cancer cells to promote androgen-independent growth and survival 
[146].  
A more recent study has shown that the endogenous “danger signal” HMGB1 protein 
was induced during prostate tumor progression in TRAMP mice, and that it was required for 
the infiltration and activation of T cells (but not B cells) within the tumor [147]. Prostate 
tumor-infiltrating T cells were shown to express LTα1β2 and, through LTβR activation in 
stromal cells, to promote the recruitment of tumor macrophages, presumably by inducing 
CCL2 expression. More importantly, LTβR signaling was shown to facilitate progression from 
hyperplasia to invasive prostate carcinoma [147]. Considering these findings with those 
obtained by Ammirante et al. (2010), it can be concluded that LTβR signaling may contribute 
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to several phases of prostate oncogenesis, through different molecular mechanisms 
(CXCL13 or CCL2 production) and involving different cellular players (T or B lymphocytes), 
and may therefore be of therapeutic value.  
 
6.3.3. Induction of a pro-tumorigenic niche supported by LTβR-expressing stromal cells 
LTβR signaling has been implicated in other epithelial cancers, as for example ovarian 
cancer [148]. Lau and co-workers detected LTA and LTB overexpression in ovarian cancer 
cells and demonstrated that LTα1β2-expressing human ovarian primary cancer cells induce 
LTβR-expressing cancer-associated fibroblasts (CAFs) to express chemokines through NF-
κB signaling. One of the chemokines identified as being induced in CAFs was CXCL11, 
which was able to promote proliferation and migration of CXCR3-expressing ovarian cancer 
cells [148]. Thus, in this setting cancer cells generate a pro-tumorigenic microenvironment 
through increased lymphotoxin expression and LTβR activation in stromal cells. 
 
6.3.4. Immune evasion mediated by LTβR 
Another way by which LTβR signaling is involved in cancer promotion is by dampening the 
host adaptive immune response to cancer. Because LTα1β2-LTβR signaling plays a role in 
immune self-tolerance due to its key role in medullary thymic epithelial cell development and 
function [4], blocking this signaling axis may rescue tumor-reactive effector T cells from 
thymic clonal deletion and thus counter cancer development [149]. To test this hypothesis, 
Zhou et al. (2009) used the TRAMP animal model co-expressing a TCR specific for SV40 
large T antigen. Targeted mutation of the Lta gene was found to impair thymic negative 
selection of tumor-reactive T cells, resulting in decreased prostate cancer incidence and in 
milder malignant phenotype. Confirming the impact of LTβR signaling in prostate 
oncogenesis, short-term LTβR blockade in TRAMP mice rescued T cells from clonal 
deletion, reduced the progression of primary prostate cancer and prevented metastasis 
[150]. This study thus suggests that LTβR signaling may constitute a non-antigen-based 
strategy of immune cancer prevention potentially useful for patients with high genetic risk for 
prostate cancer. Another report has highlighted an alternative role for LTβR in tumor 
immunoevasion. Kim and co-workers showed that the human papillomavirus 16 (HPV16) E6 
oncogene induced LTα, LTβ and LTβR expression in cervical cancer cell lines [44]. More 
importantly, LTβR signaling led to MHC class I downregulation in these cells and to 
resistance to cytotoxic T lymphocyte-mediated lytic activity [44]. Whether such mechanism 
of cancer cell evasion from the host immune system takes place in vivo and results in tumor 
progression remains to be determined. 
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7. LTβR role in hematological malignancies 
 
Several reports indicate that hematological malignancies are fostered by LTβR signaling, 
either intrinsically to cancer cells or indirectly through microenvironmental cells. Studies 
aiming to identify genetic abnormalities underlying multiple myeloma pathogenesis identified 
alterations (e.g., deletions, amplifications, and point mutations) in several NF-κB regulators, 
in about 15% of patient samples and 30-40% of cell lines [124,151]. Such alterations 
included LTBR amplification in one patient sample and one cell line [124]. Despite the low 
frequency of abnormalities in LTBR and other functionally related genes, these studies 
indicated that constitutive activation of the LTβR-activated noncanonical NF-κB pathway 
promotes multiple myeloma oncogenesis [124]. 
LTα1β2-LTβR signaling has also been shown to mediate paracrine or juxtacrine 
tumor-stroma interactions leading to microenvironment modulation and establishment of 
chemoattractive tumor-permissive niches in secondary lymphoid organs (Figure 4D). Rehm 
and co-workers identified the homeostatic chemokine receptor CCR7 as a determinant 
factor in dictating the location and survival of B-cell lymphoma cells within secondary 
lymphoid organs [152]. Using the Eµ-Myc transgenic mouse model of aggressive human B-
cell lymphoma, these researchers found that CCR7 controls lymphoma cell dissemination to 
LNs and to the splenic T-cell zone where, through LTα1β2 expression, cancer cells stimulate 
LTβR in gp38+ FRCs. This molecular crosstalk results in the expansion of stromal FRC 
networks and release of chemoattractant homeostatic chemokines (e.g., the CCR7 ligands, 
CCL19 and CCL21) and trophic factors (e.g., IHH/indian hedgehog) that confer a survival 
advantage to lymphoma cells [152]. More recently, these authors used the murine Eµ-Tcl1 
model of B-cell chronic lymphocytic leukemia to show that the CXCL13-CXCR5 signaling 
axis mediates leukemic B cell access to a stromal compartment enriched with FDCs in 
splenic B cell follicles [153]. Here, leukemic B cells and FDCs engage in a reciprocal 
crosstalk in which LTα1β2-expressing leukemic cells activate LTβR and thus stimulate the 
differentiation of FDC networks and the production of CXCL13, CCL21, and other pro-
proliferative and pro-survival growth factors [153]. In both studies, the inhibition of LTβR-
mediated interactions between malignant and microenvironmental cells impaired disease 
progression and was therefore pointed as a possible strategy to complement standard 
cytotoxic therapies [152,153]. Recently, high expression of LTα and LTβ-encoding genes 
was identified in human primary T-cell acute lymphoblastic leukemia expressing TAL or LMO 
oncogenes (TAL/LMO molecular subtype) [154]. Highlighting the relevance of these findings, 
LTβR activation in thymic stromal cells was shown to promote T-cell leukemogenesis in a 
mouse model of T-cell acute leukemia/lymphoma [154]. Leukemic cells from these mice 
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were shown to express high levels of LTα and LTβ, from an early stage, and importantly, 
both early appearance of malignant cells and mouse survival were delayed in the absence of 
stromal LTβR. Since stromal cells dependent on RelB expression were shown be involved in 
mouse leukemogenesis [155], these studies support the notion that LTβR activation in 
stromal cells promotes T-cell leukemogenesis through NF-κB activation.  
 
 
8. Signaling pathways mediating LTβR activity in cancer 
 
As highlighted in the above sections, the classical or alternative NF-κB pathways appear to 
be the main mediators of most cellular events stemming from LTβR signaling that contribute 
to its pro- and anti-oncogenic effects. However, a number of reports suggest that this is not 
always the case. In fact, some anti-oncogenic effects of LTβR signaling leading to cancer 
cell death were reported to be mediated by other downstream components such as the 
reactive oxygen species-induced apoptosis signal-regulating kinase (ASK1) [72] and 
caspases (e.g., caspase 3 and 8) [66,71,73]. On the other hand, only few pro-tumorigenic 
effects of LTβR signaling were found to result from activation of mediators other than NF-κB. 
Ammirante et al. (2010) reported that LTβR activation in prostate carcinoma cells by 
lymphotoxin expressed on B cells infiltrating regressing tumors after castration was required 
for IKKα translocation to the nucleus and STAT3 activation, nevertheless a collaboration with 
another unidentified critical cytokine/receptor activating STAT3 was predicted [146]. 
Although JNK has been shown to be activated by LTβR (Figure 2) and to be implicated in 
cancer, in promoting or suppressing it [156], no report has so far addressed whether this 
kinase is involved in cancer-related LTβR activity. 
 
 
9. Signaling pathways with context-dependent outcomes in carcinogenesis 
 
Taken together, the aforementioned reports demonstrate the dual role of LTα1β2/LIGHT-
LTβR signaling axis in cancer development. These proteins are not unique in that, other 
signaling proteins, such as tumor necrosis factor alpha (TNFα), transforming growth factor 
beta (TGFβ), NOTCH1 and NF-κB, share this context-dependent role in oncogenesis. 
 In accordance with its designation, TNF has been shown to induce apoptosis or 
necrosis in a variety of cancer cell types. TNF was shown to kill directly cancer cells [157], 
but its anti-oncogenic effects seem to involve mainly damage to the tumor vasculature 
through endothelial cell apoptosis [158,159] and the stimulation of anti-tumoral immune 
responses [160–162]. In contrast to these findings, higher levels of TNFα were detected in 
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the serum of cancer patients and in pre-neoplastic and tumor tissues, being associated with 
tumor progression [163–165]. Accordingly, in many studies, TNF was reported to prompt a 
broad range of pro-carcinogenic signaling mechanisms leading to tumor initiation and 
promotion (often in the context of chronic inflammation) including survival, proliferation, 
angiogenesis, invasion, and metastatic dissemination of cancer cells [166–170]. These 
contradictory roles in carcinogenesis seem to be associated with different tumor types and 
cellular contexts, and can be partly explained by levels of TNF production, chronic low doses 
leading to cancer development and progression and acute high doses leading to tumor 
regression [171]. 
 TGFβ signaling is known to play dual roles in cancer [172–174]. In early stages of 
carcinogenesis, TGFβ mediates tumor-suppressing effects through cell-autonomous 
mechanisms, including suppression of cell proliferation and induction of apoptosis [173,175]. 
Supporting this tumor suppressive role of TGFβ signaling, genetic and epigenetic alterations 
attenuating or inactivating TGFβ receptors and downstream signaling components were 
reported in diverse types of cancer (reviewed in [175]). TGFβ was also shown to suppress 
oncogenesis indirectly by preventing the molecular crosstalk between TGFβ receptor-
expressing stromal cells and cancer cells [176]. On the other hand, TGFβ can also promote 
tumor cell growth, invasiveness and metastasis in advanced tumors. Throughout tumor 
progression cancer cells dampen the growth-inhibitory TGFβ response, while its production 
increases in the tumor microenvironment [177]. As a consequence, by mechanisms such as 
increased chemokine expression and inflammation, immune response evasion, sustained 
angiogenesis, and epithelial-mesenchymal transitions (EMT) TGFβ leads to enhanced 
invasiveness and metastasis [177–180]. Therefore, the role played by TGFβ signaling likely 
depends on cancer type and cellular context. However, unlike LTβR signaling, TGFβ tumor-
suppressing or -promoting effects appear to rely on the stage of tumor development. 
 Notch signaling was also reported to mediate contradictory effects on oncogenesis. 
Activating mutations were identified in NOTCH1 and NOTCH2 genes in hematological 
malignancies (T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle 
cell lymphoma, and marginal cell lymphoma) and in breast adenocarcinoma [181–186]. 
Although the mechanisms are not fully understood, Myc induction seems to be a common 
downstream target in these different tumor contexts [187]. More recently, evidence was 
gathered indicating that NOTCH1 and NOTCH2 can also act as a tumor-suppressor gene in 
malignancies where inactivating mutations were detected. These included squamous cell 
carcinomas from skin, head and neck and lung [188–190] and chronic myelomonocytic 
leukemia [191]. In addition, NOTCH1 protein expression was found to mediate acute 
myeloid leukemia growth arrest and apoptosis [192,193]. The mechanisms remain to be 
identified but likely involve the resulting impaired activation of targets mediating pro-
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differentiation and anti-growth effects, and the promotion of an inflammatory state caused by 
Notch loss-of-function [187,194].  
Interestingly, the main signaling pathway downstream LTβR activation, that leading 
to NF-κB activation, has also been recognized to have opposing effects in cancer 
development. Although mutations affecting NF-κB and inhibitors of IκB kinase β (IKK) are 
rarely found in human cancer, NF-κB subunits are frequently activated, resulting from either 
the induction of upstream pathways or loss of negative feedback mechanisms. Regardless 
of the causes of NF-κB aberrant activation, these transcription factors play prominent tumor-
promoting roles, intrinsic, by rendering cancer cells resistant to apoptosis and/or highly 
proliferative, and extrinsic, by stimulating neoangiogenesis and inducing pro-invasive/pro-
metastatic inflammatory microenvironments [195]. Contrasting with a large body evidence 
supporting their pro-oncogenic action, some reports have revealed an unexpected tumor 
suppressor role for NF-κB proteins in essentially two types of scenario. First, NF-κB exhibits 
tumor suppressor activity when acting in concert with well-characterized tumor suppressors, 
like p53 and ARF. These tumor suppressors bind NF-κB subunits to repress the potentially 
tumorigenic genes normally induced by NF-κB activation, most likely in an early stage of 
cancer development before cancer cells undergo loss of the implicated tumor-suppressor 
genes [196,197]. Second, in contexts where pro-survival signals derive from other 
oncogenes, NF-κB activation may enhance cytotoxic drug-mediated senescence in tumors, 
thereby exerting a tumor suppressor function [198,199]. Therefore, the NF-κB role in 
carcinogenesis is highly dependent on the tumor stage, tumor type, and presence of specific 
genetic alterations. 
 
 
10. Conclusions 
 
Since the discovery of the lymphotoxin signaling system, several researchers have 
investigated its role in cancer, including solid and hematological malignancies. As discussed 
in this review, early studies have uncovered a potential anti-tumoral role in several cancer 
types (Table 1). LTα1β2- and/or LIGHT-induced activation of LTβR in a subset of solid 
cancers was reported to promote direct cytotoxic effects (Figure 3A) and/or indirect effects 
involving alterations in the tumor microenvironment (e.g., induction of chemokine expression 
and development of HEV), which lead to increased anti-tumoral immune response (Figure 
3B,C). These reports disclosed a role for acute LTβR activation in anti-cancer immunity and 
so this was suggested as a potential therapeutic approach. Conversely, during the last 
decade, several studies provided firm evidence that LTβR signaling can promote both solid 
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and hematological malignancy carcinogenesis. In some instances pro-oncogenic LTβR 
signaling is intrinsic to cancer cells, in others it acts in tumor-promoting microenvironmental 
cells (Table 2). In the first setting, LTβR signaling can be activated either independently of 
ligand binding due to LTBR gene amplification or other molecular events leading to LTβR 
overexpression (Figure 4A), or by increased expression of LTα1β2 and/or LIGHT in the 
microenvironment (Figure 4B and C). In the latter situation, LTβR signaling in cancer cells 
leads to the secretion of factors (e.g., homeostatic chemokines and cytokines) that stimulate 
angiogenesis (Figure 4B) and/or attract infiltrating tumor-promoting immune cells (Figure 4C) 
thus stimulating cancer progression. Finally, in the setting where LTα1β2-expressing cancer 
cells activate LTβR in stromal cells, the latter can secrete chemokines or potentially other 
factors that favor cancer progression (Figure 4D). The role of infiltrating immune cells is 
rather complex, since in some contexts these can impair tumor progression through 
induction of host-mediated immunological responses as discussed above, while in other 
contexts they support tumor development by upregulating pro-inflammatory cytokines and by 
modulating the microenvironment. The balance between tumor-suppressing and tumor-
promoting immune cell activity most likely depends on tumor stage, on the nature of 
recruited cells and on the type of factors produced by the tumor microenvironment. 
 Altogether, the reports previously cited have disclosed several factors influencing the 
pro- or anti-oncogenic activities of LTβR signaling. Several variables such as the tumor type, 
the progression stage, the cancer-intrinsic genetic and epigenetic alterations, the status of 
activated signaling pathways, the microenvironmental factors, and the experimental model 
used may ultimately determine if the overall effect of LTβR activation is pro- or anti-
tumorigenic. Moreover, the mechanisms by which LTβR may foster or counter tumor 
progression are not completely understood. Nevertheless, the classical and alternative NF-
κB signaling pathways are both activated by LTβR in all scenarios, which corroborates the 
dual role of NF-κB signaling observed in different cancer contexts [195].  
 Another important issue to consider when studying LTβR role in carcinogenesis is 
the mechanism of activation. It may be constitutively activated due to overexpression and 
self-oligomerization, or it may be activated only in the presence of its ligands. In the latter 
case, heterotypic interactions with cells present in the tumor microenvironment are usually 
involved. Furthermore, it is important to determine which LTβR ligand is involved, if LTα1β2, 
LIGHT, or both. Importantly, how ligand-induced activation of LTβR is achieved (e.g., 
membrane-bound or soluble ligand) or experimentally mimicked (e.g., lymphoid cells 
expressing the ligand, recombinant soluble ligand, or soluble or immobilized agonistic LTβR 
antibody) should be carefully considered, since they may lead to different cellular outcomes. 
For instance, it was reported that the degree of receptor clustering and the varying lifetime of 
the oligomerized states may lead to diverse cellular responses following receptor activation 
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[21,64,69]. Moreover, during the course of LTβR stimulation, which may be short or 
prolonged, different NF-κB complexes are activated and may result in the expression of 
different sets of target genes [78,80].  
 Considering the described LTβR pro-oncogenic functions and the notion that this 
receptor is most often activated by ligand binding, blockade of LTβR signaling and 
interruption of crosstalk between tumor and microenvironmental cells has been proposed as 
a therapeutic approach [200]. Because of the dual functions of LTβR in cancer development 
and progression, it is imperative to learn more about the mechanisms and contexts in which 
LTβR may exert pro-oncogenic effects, and thus pave the way for the development of 
rational and more effective cancer therapies. 
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Figure 1. LTβR, lymphotoxin and LIGHT proteins and genes. A) Genomic localization 
and exon-intron structure of LTBR, LTA, LTB, and TNFSF14/LIGHT human genes. Boxes 
represent exons, blue being coding and grey non-coding regions. B) Schematic 
representation of the LTβR, LTα, LTβ, and LIGHT protein primary structure. Numbers 
represent amino acid position. CRD, cysteine-rich domain; ECD, extracellular domain; ICD, 
intracellular domain; RBD, receptor-binding domain; SP, signal peptide; TMD, 
transmembrane domain; TRAF, TRAF protein-binding domains. C) Schematic 
representation of interaction between LTβR and its two main ligands, LTα1β2 heterotrimers 
(left) and LIGHT homotrimers (right). Blue shapes represent LTβR CRDs interacting with the 
groove formed each by 2 ligand subunits. Pink shapes represent TRAF binding domains. 
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Figure 2. LTβR-mediated signal transduction pathways leading to target gene 
expression and cell death. Activation of LTβR signaling by LIGHT or LTα1β2 can induce 
specific target gene expression and cell death. NF-κB classical pathway induction leads 
sequentially to activation of the IKK complex, IKK-mediated IκBα phosphorylation and 
subsequent degradation, nuclear translocation of RelA/p50 heterodimers, and induction of 
pro-inflammatory cytokine, chemokine, and adhesion molecule expression. On the other 
hand, the alternative NF-κB pathway relies on NIK and IKKα-dependent processing of p100 
into p52, leading to the translocation of RelB/p52 heterodimers to the nucleus where they 
activate the expression of genes mainly involved in lymphoid organogenesis and 
homeostasis. LTβR-induced activation of NIK is also involved in TNFR1-mediated RIP1-
dependent apoptosis. Furthermore, LTβR activation induces cell death by other ill- 
characterized mechanisms involving reactive oxygen species (ROS) production, ASK-1, and 
either caspase-independent or caspase-dependent apoptosis. LTβR was also shown to 
activate JNK leading to AP-1-induced gene expression in addition to cell death. 
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Figure 3. LTβR anti-oncogenic roles. Activation of LTβR signaling leads to anti-oncogenic 
effects due to three main mechanisms. A) Death of LTβR-expressing cancer cells likely 
induced by immune cells expressing LTα1β2 and/or LIGHT. B) Recruitment of anti-cancer 
LTα1β2- and/or LIGHT-expressing immune cells mediated by LTβR-expressing cancer or 
stromal cell chemokine production [112,113]. C) Increased anti-tumor immune response 
linked to high endothelial venule neogenesis triggered by LTβR stimulation of endothelial 
cells by LTα1β2-expressing DCs [118]. 
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Figure 4. LTβR pro-oncogenic roles. Activation of LTβR signaling favors oncogenesis due 
to four main mechanisms. A) Genetic alterations in the LTBR gene leading either to its 
overexpression or the expression of alternative forms, result in ligand-independent LTβR 
activation, which supports cancer cell proliferation and/or survival [65,122–124]. B) LTα1β2- 
and LIGHT-expressing lymphocytes induce pro-angiogenic factors in LTβR-expressing 
cancer cells and induce angiogenesis [140,141]. C) LTα1β2- and LIGHT-expressing 
lymphocytes induce chemokines in LTβR-expressing cancer cells, thus fostering a pro-
oncogenic inflammatory microenvironment [13,43,146,147]. D) LTα1β2-expressing cancer 
cells induce production of chemokines and pro-survival factors in LTβR-expressing tumor 
stromal cells, thus triggering cancer cell migration and favoring tumor progression [148,152–
154]. See Figure 3 for symbol legend.  
